Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.31
- Piotroski Score 2.00
- Grade Hold
- Symbol (ANTX)
- Company AN2 Therapeutics, Inc.
- Price $1.30
- Changes Percentage (22.17%)
- Change $0.24
- Day Low $1.07
- Day High $1.33
- Year High $22.22
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 01/11/2018
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.50
- High Stock Price Target $22.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.51
- Trailing P/E Ratio -0.81
- Forward P/E Ratio -0.81
- P/E Growth -0.81
- Net Income $-64,732,000
Income Statement
Quarterly
Annual
Latest News of ANTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Investors are often attracted to unprofitable companies like AN2 Therapeutics due to their growth potential. However, monitoring cash burn is crucial, as it can lead to financial troubles....
By Yahoo! Finance | 4 months ago
